Format

Send to

Choose Destination
Rheumatology (Oxford). 2012 Feb;51(2):393-6. doi: 10.1093/rheumatology/ker404. Epub 2011 Dec 30.

Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries.

Author information

1
Institute for Chronic Diseases and Ageing, University of Liverpool, Liverpool, UK. r.j.moots@liverpool.ac.uk

Abstract

OBJECTIVE:

To characterize the impact of etanercept (ETN) in AS on cost, work productivity and quality of life (QoL).

METHODS:

A Phase 4, open-label, multi-centre (UK, Scandinavia) extension study in AS. Eligible subjects (n = 84) were treated for 36-52 weeks with ETN 50 mg s.c. once weekly. Analysis included direct costs (transformed out-patient and in-patient care elements), indirect costs (sick leave and lost working days), efficacy and QoL.

RESULTS:

Annualized direct and indirect costs decreased (55.5%, P ≤ 0.008) during ETN treatment, as did out-patient and in-patient episodes (physiotherapist/physician visits, P = 0.012). Work productivity and QoL increased.

CONCLUSION:

ETN therapy significantly reduces direct and indirect health-care costs and increases work ability and QoL in AS. Trial Registration. EUDRACT, https://eudract.ema.europa.eu/, 2006-001061-42.

PMID:
22210658
DOI:
10.1093/rheumatology/ker404
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center